Global Diabetic Macular Edema Market Insights, Forecast and Report 2030

January 11 19:20 2022

DelveInsight’s Diabetic Macular Edema Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Diabetic Macular Edema market share of the individual therapies, current and forecasted Diabetic Macular Edema market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).


Diabetic Macular Edema Overview

Diabetic Macular Edema (DME) is triggered by Diabetic Retinopathy (DR), a well-known complication of diabetes. DR is the most prevalent diabetic eye disease and the leading cause of irreversible blindness in people in their working years in the developed and other developing countries.


Some of the key highlights of the Diabetic Macular Edema market report

  • The total prevalent population of DME in the EU-5 countries in 2020 was 641,865. These cases are expected to rise by 2030, during the forecast period, i.e., 2021–2030.
  • Among the EU-5 countries, the highest number of cases of DME were in Germany, i.e. 220,533 cases in the year 2020.
  • The prevalence of total diabetes defined by the WHO criteria increased from 9.7% in 2007 to 11.2% in 2017 among adults living in China.
  • Findings from various secondary studies suggest that DME affects more males as compared to females.
  • Diabetic Macular Edema market companies are included like Adverum Biotechnologies, Graybug Vision, Roche, Novartis, KalVista Pharmaceuticals, Ocuphire Pharma, Oxurion, YD Life Science, Novartis, Allergan (AbbVie)/Molecular Partners, Allergo Opthalmics/ Bausch Health, Kodiak Sciences, Clearside Biomedical and many others.
  • Diabetic Macular Edema therapies are included like Lucentis (Ranibizumab), Eylea (Aflibercept), Beovu (RTH258; brolucizumab), Faricimab (RG 7716), KSI-301, ADVM-022, GB-102, THR-149, LKA651, and many others.


Download sample report-


Diabetic Macular Edema symptoms include-

It includes dark spots like a smudge on glasses or gaps may appear in the vision, Blurred vision, Double vision, colours can fade or the affected person may find bright light or glare difficult.


Diabetic Macular Edema Diagnosis include-

Tests that helps in the diagnosis of DME are Visual Acuity, Refractive Error examination, Fluorescein Angiography, Optical coherence tomography scan, Pupil examination, Slit-lamp examination and Retinal Examination.


Diabetic Macular Edema Treatment include-

Treatment mainly involves the usage of Anti-VEGF Drugs, Corticosteroids and Laser photocoagulation. Nonsteroidal anti-inflammatory drugs (NSAIDs), in the form of eye drops, are sometimes used either before or after cataract surgery to prevent the development of macular edema.


Diabetic Macular Edema Market Barriers

  • Exorbitant cost
  • Shortage of trained ophthalmologists
  • Lack of awareness of eye conditions


Diabetic Macular Edema Market Drivers

  • Increasing changes in lifestyle
  • Addressing barriers to screening
  • Personalization of treatment


Diabetic Macular Edema Market Companies

  • Adverum Biotechnologies
  • Graybug Vision
  • Roche
  • Novartis
  • KalVista Pharmaceuticals
  • Ocuphire Pharma
  • Oxurion
  • YD Life Science
  • Novartis
  • Allergan (AbbVie)/Molecular Partners
  • Allergo Opthalmics/ Bausch Health
  • Kodiak Sciences
  • Clearside Biomedical
  • And many others


Learn More about Key Players working in the domain @


Diabetic Macular Edema Therapies

  • Lucentis (Ranibizumab),
  • Eylea (Aflibercept),
  • Beovu (RTH258; brolucizumab),
  • Faricimab (RG 7716),
  • KSI-301,
  • ADVM-022,
  • GB-102,
  • THR-149,
  • LKA651,
  • And many others.


Get detailed information about the pipeline therapies @


Table of content

  1. Key Insights
  2. Report Introduction
  3. Diabetic Macular Edema Market Overview at a Glance
  4. Executive Summary of Diabetic Macular Edema
  5. Epidemiology and Market Forecast Flow
  6. Disease Background and Overview
  7. Current Treatment
  8. Epidemiology and Patient Population
  9. Patient Journey
  10. Key Endpoints in Diabetic Macular Edema
  11. Marketed Therapies
  12. Emerging Therapies
  13. Conjoint Analysis of DME Therapies
  14. Diabetic Macular Edema: Seven Major Market Analysis
  15. Market Access and Reimbursement
  16. Market Drivers
  17. Market Barriers
  18. SWOT Analysis
  19. Unmet Needs
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer
  23. About DelveInsight


Speak to our expert here-


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States